A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
Phase of Trial: Phase IV
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Jun 2017 Planned End Date changed from 31 May 2024 to 1 Jul 2024.
- 07 Jun 2017 Planned primary completion date changed from 31 May 2024 to 1 Jul 2024.
- 07 Jun 2017 Status changed from not yet recruiting to recruiting.